Scienture Holdings (SCNX)
NASDAQ:SCNX
Want to see SCNX full AI Analyst Report?
SCNX Stock Chart & Stats
$0.55
-$0.13(-2.47%)
At close: 4:00 PM EST
$0.55
-$0.13(-2.47%)
Day’s Range― - ―
52-Week Range$0.24 - $2.60
Previous CloseN/A
Volume1.53K
Average Volume (3M)4.08M
Market Cap
$15.51M
Enterprise Value-$3.53B
Total Cash (Recent Filing)$3.54B
Total Debt (Recent Filing)$10.00M
Price to Earnings (P/E)―
Beta3.44
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,630,814
10 Day Avg. Volume11,411,402
30 Day Avg. Volume4,082,790
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.12
Price to Sales (P/S)181.35
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-227.35
Enterprise Value/Revenue-7.38K
Enterprise Value/Gross Profit35.69K
Enterprise Value/Ebitda89.40
Forecast
1Y Price Target
$1.50Price Target Upside172.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance-sheet FlexibilityVery low reported leverage and near-zero debt-to-equity materially reduce near-term solvency risk and preserve strategic optionality. This structural balance-sheet strength supports continued R&D and commercialization spending without immediate refinancing pressure, improving runway versus highly leveraged peers.
Meaningful TTM Revenue AccelerationAn extreme TTM revenue jump indicates tangible commercial or adoption progress that could underpin future scale. If sustained, top-line momentum creates a base for margin recovery and operating leverage, making long-term profitability more attainable as fixed costs are spread and pricing or mix improvements persist.
Continuity Via Experienced Interim Finance LeadershipAppointing an internal, experienced co-CEO as interim CFO maintains institutional knowledge and financial oversight during transition. This reduces execution risk around reporting, covenant compliance, and fundraising, supporting steadier strategic execution and investor communication during a sensitive financing and commercialization phase.
Bears Say
Material Negative Operating Cash FlowSustained negative operating and free cash flow indicate the business consumes cash to fund operations and growth, creating ongoing reliance on external financing. Over months this depletes liquidity, forces dilutive capital raises or costly debt, and limits ability to self-fund commercialization and product development.
Deep, Persistent Operating LossesLarge, persistent operating and below-the-line losses demonstrate the cost structure currently outstrips revenue even after a revenue jump. This undermines return on invested capital, erodes equity value over time, and requires either sustained top-line improvement or structural cost reductions to achieve durable profitability.
Restrictive Structured Financing Increases Operational ConstraintsThe recent secured notes provide liquidity but impose tight covenants, broad collateral claims and punitive default mechanics. These structural constraints limit capital-structure flexibility, can accelerate repayment or increase costs on covenant breaches, and raise the risk of forced actions that impair long-term strategic options.
Scienture Holdings News
SCNX FAQ
What was Scienture Holdings’s price range in the past 12 months?
Scienture Holdings lowest stock price was $0.24 and its highest was $2.60 in the past 12 months.
What is Scienture Holdings’s market cap?
Scienture Holdings’s market cap is $15.51M.
When is Scienture Holdings’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Scienture Holdings’s earnings last quarter?
Currently, no data Available
Is Scienture Holdings overvalued?
According to Wall Street analysts Scienture Holdings’s price is currently Undervalued.
Does Scienture Holdings pay dividends?
Scienture Holdings pays a Notavailable dividend of $1.5 which represents an annual dividend yield of N/A. See more information on Scienture Holdings dividends here
What is Scienture Holdings’s EPS estimate?
Scienture Holdings’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scienture Holdings have?
Scienture Holdings has 40,630,814 shares outstanding.
What happened to Scienture Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scienture Holdings?
Currently, no hedge funds are holding shares in SCNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scienture Holdings
As a health services IT enterprise, TRxADE HEALTH, Inc. manages an online platform designed to facilitate transactions between licensed pharmaceutical wholesalers and healthcare providers. This digital marketplace enables wholesalers to distribute a broad spectrum of products and services, encompassing branded and generic drugs as well as other non-pharmaceutical items. Customers for these offerings span government organizations, hospitals, medical clinics, and independent pharmacies. The firm's corporate base is situated in Tampa, Florida.
SCNX Stock 12 Month Forecast
Average Price Target
$1.50
▲(172.73% Upside)
Technical Analysis
Ownership Overview
16.82% Insiders
1.70% Mutual Funds
<0.01% Other Institutional Investors
80.47% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---